BX slides 7% as options defensiveness builds into sector-wide pullback

Blackstone heads into the end of this week with a notable disconnect: short sellers have continued to exit, yet the stock has fallen nearly 7% — the pressure is coming from price action, not from a rebuilding short base.

The price move is the dominant story. BX closed at $114.26 on Tuesday, down 6.9% on the week and off 11.5% over the past month. That weakness is sector-wide rather than idiosyncratic: close peers KKR and TPG fell 6.6% and 8.5% respectively, while Carlyle dropped 9%. ARES held up better, off just 2.1%, suggesting some differentiation within the alt-asset complex. The selloff has more to do with macro sentiment around private markets than any company-specific deterioration.

Short positioning tells a quieter story — and has continued the retreat flagged in the previous note. Short interest has declined further to 2.1% of the free float, down roughly 5% on the week and down 31% over the past month. That follow-through from last week's sharp unwind confirms that the short base is not rebuilding into the price weakness. Borrow conditions remain entirely relaxed: availability is running near 2,270% — roughly 22 times the shares currently on loan — and the cost to borrow has dropped 35% on the week to just 0.34%. The ORTEX short score has edged lower again to 31.8, its weakest reading in the recent history. Together, this lending market picture is as uncrowded as it gets.

Options positioning has picked up some of the defensive slack. The put/call ratio is at 1.56, slightly above its 20-day average of 1.52 — not an extreme reading, but tracking higher into the weakness. The z-score of 1.28 places it in the upper half of its recent range without reaching alarm levels; the 52-week high on the PCR is 1.87, so there is room to run before the options market looks genuinely stressed. The modest defensiveness aligns with investors hedging into the down move rather than expressing a strong directional view.

The Street remains broadly constructive despite the recent target trimming. TD Cowen lowered its price target to $133 this week — the second cut from that desk in a month — while maintaining its Buy rating, implying the firm sees the pullback as a valuation opportunity rather than a fundamental concern. JP Morgan and Piper Sandler are both Neutral, with targets around $130-$136. Morgan Stanley cut its target sharply to $184 from $215 in late April, also retaining Overweight. The consensus mean target of $143.55 represents roughly 26% upside to current levels — a wide gap that reflects how quickly the stock has decompressed from earlier highs. On valuation, the price-to-book has dropped by 1.2x over the past month to 9.8x, and the P/E has compressed by 2.1x to 17.5x — the multiple is derating in real time alongside the price. The forward EPS growth score ranks in the 74th percentile, suggesting the fundamental case remains intact even as the market re-prices the near-term multiple.

Q1 earnings — reported on April 23 — produced a 6.2% single-day drop and a further 3.2% loss over the following five sessions. That post-earnings pressure has not yet fully unwound, and the stock is now well below the level at which it entered that print. What to watch from here is whether the sector-wide derating continues to drag BX lower in sympathy, or whether the absence of any meaningful short rebuilding becomes a floor as the price approaches the lower end of analyst targets.